{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:12Z","timestamp":1792131012368,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Accure Therapeutics Sl","award":["001"],"award-info":[{"award-number":["001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>OCS-05 (aka BN201) is a peptidomimetic that binds to serum glucocorticoid kinase-2 (SGK2), displaying neuroprotective activity. The objective of this randomized, double-blind 2-part study was to test safety and pharmacokinetics of OCS-05 administered by intravenous (i.v.) infusion in healthy volunteers. Subjects (n\u2009=\u200948) were assigned to receive placebo (n\u2009=\u200912) or OCS-05 (n\u2009=\u200936). , Doses tested were 0.05, 0.2, 0.4, 0.8, 1.6, 2.4 and 3.2\u00a0mg\/kg in the single ascending dose (SAD) part. In the multiple ascending dose (MAD) part, 2.4 and 3.0\u00a0mg\/kg doses were administered with 2\u00a0h i.v. infusion for 5 consecutive days. Safety assessments included adverse events, blood tests, ECG, Holter monitoring, brain MRI and EEG. No serious adverse events were reported in the OCS-05 group (there was one serious adverse event in the placebo group). Adverse events reported in the MAD part were not clinically significant, and no changes on the ECG, EEG or brain MRI were observed. Single-dose (0.05\u20133.2\u00a0mg\/kg) exposure (C<jats:sub>max<\/jats:sub> and AUC) increased in a dose-proportional manner. Steady state was reached by Day 4 and no accumulation was observed. Elimination half-life ranged from 3.35 to 8.23\u00a0h (SAD) and 8.63 to 12.2\u00a0h (MAD). Mean individual C<jats:sub>max<\/jats:sub> concentrations in the MAD part were well below the safety thresholds. OCS-05 administered as 2-h i.v. infusions of multiple doses up to 3.0\u00a0mg\/Kg daily for up to 5 consecutive days was safe and well tolerated. Based on this safety profile, OCS-05 is currently being tested in a phase 2 trial in patient with acute optic neuritis (NCT04762017, date registration 21\/02\/2021).<\/jats:p>","DOI":"10.1038\/s41598-023-32278-0","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T10:02:54Z","timestamp":1680084174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Pablo","family":"Villoslada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelize","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"32278_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/13543784.2020.1757647","volume":"29","author":"P Villoslada","year":"2020","unstructured":"Villoslada, P. & Steinman, L. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opin. Investig. Drugs 29, 443\u2013459 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"32278_CR2","doi-asserted-by":"publisher","first-page":"136194","DOI":"10.1016\/j.neulet.2021.136194","volume":"764","author":"E Dremencov","year":"2021","unstructured":"Dremencov, E. et al. Trophic factors as potential therapies for treatment of major mental disorders. Neurosci. Lett. 764, 136194 (2021).","journal-title":"Neurosci. Lett."},{"key":"32278_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/978-1-4939-7825-0_24","volume":"1780","author":"M Savolainen","year":"2018","unstructured":"Savolainen, M., Emerich, D. & Kordower, J. H. Disease modification through trophic factor delivery. Methods Mol. Biol. 1780, 525\u2013547 (2018).","journal-title":"Methods Mol. Biol."},{"key":"32278_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.exer.2017.01.007","volume":"157","author":"DJ Calkins","year":"2017","unstructured":"Calkins, D. J., Pekny, M., Cooper, M. L., Benowitz, L., Lasker IIoA, Glaucomatous Neurodegeneration P. The challenge of regenerative therapies for the optic nerve in glaucoma. Exp. Eye Res. 157, 28\u201333 (2017).","journal-title":"Exp. Eye Res."},{"key":"32278_CR5","doi-asserted-by":"publisher","first-page":"104896","DOI":"10.1016\/j.neubiorev.2022.104896","volume":"142","author":"S Bhalla","year":"2022","unstructured":"Bhalla, S., Mehan, S., Khan, A. & Rehman, M. U. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci. Biobehav. Rev. 142, 104896 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"32278_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrn3209","volume":"13","author":"AM Fernandez","year":"2012","unstructured":"Fernandez, A. M. & Torres-Aleman, I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 13, 225\u2013239 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"32278_CR7","doi-asserted-by":"crossref","unstructured":"Gui T, Burgering BMT. FOXOs: masters of the equilibrium. FEBS J 2021.","DOI":"10.1111\/febs.16221"},{"key":"32278_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-020-0088-2","volume":"20","author":"G Calissi","year":"2021","unstructured":"Calissi, G., Lam, E. W. & Link, W. Therapeutic strategies targeting FOXO transcription factors. Nat. Rev. Drug. Discov. 20, 21\u201338 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"32278_CR9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.12688\/f1000research.15258.1","volume":"7","author":"RJ Stefanetti","year":"2018","unstructured":"Stefanetti, R. J., Voisin, S., Russell, A. & Lamon, S. Recent advances in understanding the role of FOXO3. F1000Research 7, 1372 (2018).","journal-title":"F1000Research"},{"key":"32278_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1128\/MCB.21.3.952-965.2001","volume":"21","author":"A Brunet","year":"2001","unstructured":"Brunet, A. et al. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell Biol. 21, 952\u2013965 (2001).","journal-title":"Mol. Cell Biol."},{"key":"32278_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s13311-019-00717-4","volume":"16","author":"P Villoslada","year":"2019","unstructured":"Villoslada, P. et al. Axonal and myelin neuroprotection by the peptoid BN201 in brain inflammation. Neurotherapeutics 16, 808\u2013827 (2019).","journal-title":"Neurotherapeutics"},{"key":"32278_CR12","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.1016\/S0021-9258(19)50221-6","volume":"268","author":"MK Webster","year":"1993","unstructured":"Webster, M. K., Goya, L. & Firestone, G. L. Immediate-early transcriptional regulation and rapid mRNA turnover of a putative serine\/threonine protein kinase. J. Biol. Chem. 268, 11482\u201311485 (1993).","journal-title":"J. Biol. Chem."},{"key":"32278_CR13","first-page":"2031","volume":"13","author":"MK Webster","year":"1993","unstructured":"Webster, M. K., Goya, L., Ge, Y., Maiyar, A. C. & Firestone, G. L. Characterization of SGK, a novel member of the serine\/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol. Cell Biol. 13, 2031\u20132040 (1993).","journal-title":"Mol. Cell Biol."},{"key":"32278_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0016-5085(99)70011-9","volume":"116","author":"S Waldegger","year":"1999","unstructured":"Waldegger, S. et al. h-sgk serine-threonine protein kinase gene as transcriptional target of transforming growth factor beta in human intestine. Gastroenterology 116, 1081\u20131088 (1999).","journal-title":"Gastroenterology"},{"key":"32278_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/jlb.67.2.240","volume":"67","author":"RT Cowling","year":"2000","unstructured":"Cowling, R. T. & Birnboim, H. C. Expression of serum- and glucocorticoid-regulated kinase (sgk) mRNA is up-regulated by GM-CSF and other proinflammatory mediators in human granulocytes. J. Leukoc. Biol. 67, 240\u2013248 (2000).","journal-title":"J. Leukoc. Biol."},{"key":"32278_CR16","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1073\/pnas.94.9.4440","volume":"94","author":"S Waldegger","year":"1997","unstructured":"Waldegger, S., Barth, P., Raber, G. & Lang, F. Cloning and characterization of a putative human serine\/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc. Natl. Acad. Sci. U.S.A. 94, 4440\u20134445 (1997).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"32278_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0169-328X(94)90090-6","volume":"26","author":"K Imaizumi","year":"1994","unstructured":"Imaizumi, K., Tsuda, M., Wanaka, A., Tohyama, M. & Takagi, T. Differential expression of sgk mRNA, a member of the Ser\/Thr protein kinase gene family, in rat brain after CNS injury. Brain Res. Mol. Brain Res. 26, 189\u2013196 (1994).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"32278_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1152\/physrev.00050.2005","volume":"86","author":"F Lang","year":"2006","unstructured":"Lang, F. et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol. Rev. 86, 1151\u20131178 (2006).","journal-title":"Physiol. Rev."},{"key":"32278_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/18744672112059990028","volume":"6","author":"D Baines","year":"2013","unstructured":"Baines, D. Kinases as targets for ENaC regulation. Curr. Mol. Pharmacol. 6, 50\u201364 (2013).","journal-title":"Curr. Mol. Pharmacol."},{"key":"32278_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev.physiol.68.040104.131654","volume":"68","author":"J Loffing","year":"2006","unstructured":"Loffing, J., Flores, S. Y. & Staub, O. Sgk kinases and their role in epithelial transport. Annu. Rev. Physiol. 68, 461\u2013490 (2006).","journal-title":"Annu. Rev. Physiol."},{"key":"32278_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/brain\/aws325","volume":"136","author":"T Arun","year":"2013","unstructured":"Arun, T. et al. Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride. Brain 136, 106\u2013115 (2013).","journal-title":"Brain"},{"key":"32278_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/brain\/awq337","volume":"134","author":"S Vergo","year":"2011","unstructured":"Vergo, S. et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 134, 571\u2013584 (2011).","journal-title":"Brain"},{"key":"32278_CR23","doi-asserted-by":"publisher","first-page":"11299","DOI":"10.1523\/JNEUROSCI.5910-11.2012","volume":"32","author":"X Chen","year":"2012","unstructured":"Chen, X. et al. Neurotrophic effects of serum- and glucocorticoid-inducible kinase on adult murine mesencephalic dopamine neurons. J. Neurosci. 32, 11299\u201311308 (2012).","journal-title":"J. Neurosci."},{"key":"32278_CR24","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.1523\/JNEUROSCI.0006-05.2005","volume":"25","author":"S David","year":"2005","unstructured":"David, S. et al. Expression of serum- and glucocorticoid-inducible kinase is regulated in an experience-dependent manner and can cause dendrite growth. J. Neurosci. 25, 7048\u20137053 (2005).","journal-title":"J. Neurosci."},{"key":"32278_CR25","first-page":"1282","volume":"6","author":"X Wu","year":"2013","unstructured":"Wu, X. et al. Dynamic change of SGK expression and its role in neuron apoptosis after traumatic brain injury. Int. J. Clin. Exp. Pathol. 6, 1282\u20131293 (2013).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"32278_CR26","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1038\/sj.onc.1209086","volume":"24","author":"EL Greer","year":"2005","unstructured":"Greer, E. L. & Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410\u20137425 (2005).","journal-title":"Oncogene"},{"key":"32278_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fphys.2013.00147","volume":"4","author":"J Hagenbuchner","year":"2013","unstructured":"Hagenbuchner, J. & Ausserlechner, M. J. Mitochondria and FOXO3: Breath or die. Front. Physiol. 4, 147 (2013).","journal-title":"Front. Physiol."},{"key":"32278_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857\u2013868 (1999).","journal-title":"Cell"},{"key":"32278_CR29","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1073\/pnas.96.13.7421","volume":"96","author":"WH Biggs 3rd","year":"1999","unstructured":"Biggs, W. H. 3rd., Meisenhelder, J., Hunter, T., Cavenee, W. K. & Arden, K. C. Protein kinase B\/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U.S.A. 96, 7421\u20137426 (1999).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"32278_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1677\/JOE-06-0191","volume":"193","author":"DA Glauser","year":"2007","unstructured":"Glauser, D. A. & Schlegel, W. The emerging role of FOXO transcription factors in pancreatic beta cells. J. Endocrinol. 193, 195\u2013207 (2007).","journal-title":"J. Endocrinol."},{"key":"32278_CR31","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/onc.2008.21","volume":"27","author":"DR Calnan","year":"2008","unstructured":"Calnan, D. R. & Brunet, A. The FoxO code. Oncogene 27, 2276\u20132288 (2008).","journal-title":"Oncogene"},{"key":"32278_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00125-004-1327-5","volume":"47","author":"Q Wang","year":"2004","unstructured":"Wang, Q. et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47, 478\u2013487 (2004).","journal-title":"Diabetologia"},{"key":"32278_CR33","doi-asserted-by":"publisher","first-page":"e1003141","DOI":"10.1371\/journal.pgen.1003141","volume":"8","author":"A Calixto","year":"2012","unstructured":"Calixto, A., Jara, J. S. & Court, F. A. Diapause formation and downregulation of insulin-like signaling via DAF-16\/FOXO delays axonal degeneration and neuronal loss. PLoS Genet 8, e1003141 (2012).","journal-title":"PLoS Genet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32278-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32278-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T10:11:01Z","timestamp":1680084661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32278-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32278"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32278-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PV holds a patent covering the composition of matter and uses of BN201. PV is a founder, holds stocks in Bionure SL, which has licensed the patent rights to Oculis SL and serves on its scientific advisory board, having been compensated by such activities. MM and SP were employees of Accure Therapeutics (formerly Bionure SL), and SH and AK were employees of Simbec-Orion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5099"}}